Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer
Status:
Terminated
Trial end date:
2005-07-18
Target enrollment:
Participant gender:
Summary
Current therapies for Stage IV Pancreatic Cancer provide very limited benefit to the patient.
The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in
the treatment of Stage IV Pancreatic Cancer.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Stage IV Pancreatic Cancer.